{
    "organizations": [],
    "uuid": "98a0a0142974198bf7e2f49b8c1c912cfe44cb88",
    "author": "",
    "url": "https://www.reuters.com/article/brief-vertex-pharmaceuticals-reports-q4/brief-vertex-pharmaceuticals-reports-q4-shr-of-0-39-idUSB8N1LI03A",
    "ord_in_thread": 0,
    "title": "BRIEF-Vertex Pharmaceuticals Reports Q4 Shr of $0.39",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 26 PM / Updated 12 minutes ago BRIEF-Vertex Pharmaceuticals Reports Q4 Shr of $0.39 Reuters Staff 2 Min Read \nJan 31 (Reuters) - Vertex Pharmaceuticals Inc: \n* VERTEX PHARMACEUTICALS - QTRLY EARNINGS PER SHARE $0.39; QTRLY NON-GAAP EARNINGS PER SHARE $0.61; QTRLY TOTAL REVENUES $651.6 MILLION VERSUS $458.7 MILLION \n* VERTEX PHARMACEUTICALS INC Q4 EARNINGS PER SHARE VIEW $0.53, REVENUE VIEW $594.7 MILLION -- THOMSON REUTERS I/B/E/S \n* VERTEX PHARMACEUTICALS - QTRLY TOTAL CF NET PRODUCT REVENUES INCREASED 37 PERCENT TO $621.2 MILLION FROM $454 MILLION FOR Q4 2016 \n* VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM ORKAMBI INCREASED 32 PERCENT TO $365.4 MILLION FROM $276.9 MILLION FOR Q4 2016 \n* VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM KALYDECO INCREASED 44 PERCENT TO $255.8 MILLION FROM $177.1 MILLION FOR Q4 2016 \n* VERTEX PHARMACEUTICALS - EXPECTS COMBINED GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE IN 2018 WILL BE IN RANGE OF $1.80 BILLION TO $1.95 BILLION \n* VERTEX PHARMACEUTICALS - SEES 2018 COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION \n* VERTEX PHARMACEUTICALS - PLANS TO PROVIDE TOTAL CF PRODUCT REVENUE GUIDANCE FOR FY 2018 UPON ANTICIPATED FDA APPROVAL OF TEZACAFTOR/IVACAFTOR COMBINATION \n* VERTEX PHARMACEUTICALS - BOARD AUTHORIZED SHARE REPURCHASE PROGRAM OF UP TO $500 MILLION OF COMMON STOCK THROUGH DEC 31, 2019 \n* VERTEX PHARMACEUTICALS - REPURCHASE PROGRAM IS EXPECTED TO BE EXECUTED OVER TWO YEARS Source text for Eikon: Further company coverage:",
    "published": "2018-01-31T23:25:00.000+02:00",
    "crawled": "2018-01-31T23:43:17.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "report",
        "q4",
        "shr",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "pharmaceutical",
        "qtrly",
        "earnings",
        "per",
        "share",
        "qtrly",
        "earnings",
        "per",
        "share",
        "qtrly",
        "total",
        "revenue",
        "million",
        "versus",
        "million",
        "vertex",
        "pharmaceutical",
        "inc",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "vertex",
        "pharmaceutical",
        "qtrly",
        "total",
        "cf",
        "net",
        "product",
        "revenue",
        "increased",
        "percent",
        "million",
        "million",
        "q4",
        "vertex",
        "pharmaceutical",
        "qtrly",
        "net",
        "product",
        "revenue",
        "orkambi",
        "increased",
        "percent",
        "million",
        "million",
        "q4",
        "vertex",
        "pharmaceutical",
        "qtrly",
        "net",
        "product",
        "revenue",
        "kalydeco",
        "increased",
        "percent",
        "million",
        "million",
        "q4",
        "vertex",
        "pharmaceutical",
        "expects",
        "combined",
        "gaap",
        "research",
        "development",
        "sg",
        "expense",
        "range",
        "billion",
        "billion",
        "vertex",
        "pharmaceutical",
        "see",
        "combined",
        "research",
        "development",
        "sg",
        "expense",
        "range",
        "billion",
        "billion",
        "vertex",
        "pharmaceutical",
        "plan",
        "provide",
        "total",
        "cf",
        "product",
        "revenue",
        "guidance",
        "fy",
        "upon",
        "anticipated",
        "fda",
        "approval",
        "combination",
        "vertex",
        "pharmaceutical",
        "board",
        "authorized",
        "share",
        "repurchase",
        "program",
        "million",
        "common",
        "stock",
        "dec",
        "vertex",
        "pharmaceutical",
        "repurchase",
        "program",
        "expected",
        "executed",
        "two",
        "year",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}